Effects of salt and protein intake on polyuria in V2RA-treated ADPKD patients.

Abstract

The only treatment proven to be renoprotective in autosomal dominant polycystic kidney disease (ADPKD) is a vasopressin V2-receptor antagonist (V2RA). However, aquaresis-associated side effects limit tolerability. We investigated whether salt and/or protein intake influences urine volume and related endpoints in V2RA-treated ADPKD patients. In this randomized, controlled, double-blind, crossover trial, ADPKD patients treated with maximally tolerated dose of a V2RA were included. While on a low salt and low protein diet, patients were given additional salt and protein to mimic regular intake, which was subsequently replaced by placebo in random order during four 2-week periods. Primary endpoint was change in 24-h urine volume. Secondary endpoints were change in quality of life, measured glomerular filtration rate (mGFR), blood pressure and copeptin level. Twelve patients (49±8years, 25.0% male) were included. Baseline salt and protein intake were 10.8±1.3g/24-h and 1.2±0.2g/kg/24-h, respectively. During the low salt and low protein treatment periods, intake decreased to 5.8±1.6g/24-h and 0.8±0.1g/kg/24-h, respectively. Baseline 24-h urine volume (5.9±1.2L) decreased to 5.2±1.1L (-11%, P=.004) on low salt and low protein, and to 5.4±0.9L (-8%, P=.04) on low salt. Reduction in 24-h urine volume was two times greater in patients with lower urine osmolality (-16% vs -7%). Polyuria quality of life scores improved in concordance with changes in urine volume. mGFR decreased during the low salt and low protein, while mean arterial pressure did not change during study periods. Plasma copeptin decreased significantly during low salt and low protein periods. Lowering dietary salt and protein intake has a minor effect on urine volume in V2RA-treated ADPKD patients. Reduced intake of osmoles decreased copeptin concentrations and might thus increase the renoprotective effect of a V2RA in ADPKD patients.